Clinical Trial Update: Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

This document reports a completed Phase 1/2 clinical trial evaluating XL147 (SAR245408) or XL765 (SAR245409) in combination with letrozole for breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Letrozole (letrozole)
• XL147 (SAR245408)
• XL765 (SAR245409)

Snippet

Sponsor: Sanofi | Conditions: Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED